The bolt-on deal gives Merck access to a series of preclinical-stage TRPML1 agonists which Calporta is developing as treatments for various lysosomal storage and neurodegenerative disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback